共查询到17条相似文献,搜索用时 596 毫秒
1.
环糊精及其衍生物在多肽/蛋白质类药物非注射给药体系中的应用 总被引:1,自引:0,他引:1
目前,多肽/蛋白质类药物多数需要采用注射剂型给药以确保其生物利用度。开发易于给药、病人顺应性高以及治疗费用更低的非注射剂型是非常有意义的。然而,多肽/蛋白质类药物直接进行非注射给药的生物利用度通常非常低,需要制备具有设计功能的载药系统,例如加入不同比例的酶抑制剂、吸收促进剂等以提高生物利用度。环糊精及其衍生物由于其能与客体分子形成包合物的特性,以及对粘膜的促渗透作用等,在多肽/蛋白质药物的非注射给药系统中获得了日益广泛的应用。综述了近年来环糊精及其衍生物在多肽/蛋白质类药物非注射给药体系中的应用情况。 相似文献
2.
3.
4.
多肽类药物制剂研究现状 总被引:1,自引:0,他引:1
多肽类药物制剂研究所面临的主要问题是多肽的不稳定性、体内半衰期短和生物膜透过性差。本文综述了(1)引起多肽不稳定性的原因;(2)提高多肽稳定性的方法;(3)多肽类药物制剂货架时间的确定;(4)多肽类药物的分析手段;(5)多肽类药物的控释研究;(6)多肽的非注射途径给药研究。最后提出了多肽类药物制剂研究的展望。 相似文献
5.
生物可降解聚合物纳米粒给药载体 总被引:4,自引:0,他引:4
生物可降解聚合物纳米粒用于给药载体具有广阔的前景。本文综述了生物可降解聚合物纳米粒给药载体领域的最新进展 :包括纳米粒表面修饰特性、药物释放、载多肽和蛋白质等生物大分子药物传输中的潜在应用。 相似文献
6.
聚乙二醇化修饰对蛋白多肽药物药代动力学的影响 总被引:1,自引:0,他引:1
聚乙二醇(PEG)化修饰在生物制药领域被认为是改变蛋白多肽类药物生物、理化性质的最佳方法之一。众多研究表明,PEG化后的蛋白多肽在生物体内的药代动力学行为有了很大改变,主要表现在:吸收相半衰期及消除相半衰期延长.血药峰浓度提高,达峰时间滞后,表观分布容积变小,免疫反应性减弱,血浆清除减慢。这些变化极大地改善了蛋白多肽药物在机体内清除快、免疫原性高、有效血药浓度持续时间短、需频繁给药等缺点。聚乙二醇化修饰为生物制药领域开辟了新的天地。 相似文献
7.
多肽、蛋白类药物脂质体的研究进展 总被引:1,自引:0,他引:1
脂质体做为多肽、蛋白类药物一种新型给药载体有控制药物释放、降低药物的毒性、提高药物的靶向性等突出优点,具有广阔的应用前景。本文通过查阅近10年来多肽和蛋白类药物脂质体研究的相关资料,总结论述了脂质体作为多肽、蛋白类药物载体在新的制备方法、新型脂质体、给药途径、产业化进展四个方面的最新研究动向,指出了多肽、蛋白类药物脂质体在研究应用中存在的不足,并展望了多肽、蛋白类药物脂质体未来发展的方向。 相似文献
8.
脂质纳米粒是由固体脂肪酸或其酯类制成的一类纳米制剂,其生物相容性好、安全性好,所以在药物递送领域受到广泛关注.难溶性药物、多肽及蛋白质药物由于溶解度、跨膜能力以及稳定性等问题,导致口服生物利用度低,而利用脂质纳米粒作为其载体,口服给药后能显著改善药物的生物利用度,这使得脂质纳米粒在口服给药系统中得到了广泛的应用与研究.本文从口服脂质纳米粒的处方、制备工艺、吸收机制以及应用四个方面对其进行了详细的综述. 相似文献
9.
复杂的肿瘤微环境导致抗肿瘤药物在肿瘤组织内递送效率低下,严重阻碍了药物对浅表肿瘤的治疗效果。生物相容透皮给药微针凭借较高的机械强度,刺穿皮肤角质层,将微针内的药物递送至浅表肿瘤组织内,提高生物利用度,改善静脉注射、口服给药的肝肾毒性等问题。本文介绍了生物相容透皮给药微针的设计及其在癌症化疗、光动力治疗、光热治疗、免疫治疗、基因治疗等领域的研究进展,对浅表肿瘤的微创、局部递药和精准、高效治疗具有重要指导意义。 相似文献
10.
实现抗癌药物的口服给药,对于癌症的化疗及患者的生活会有很大的方便性。但大多数抗癌药物直接口服给药时,由于受到胃肠道的屏蔽作用导致生物利用度降低,所以寻找一种有效的药物载体,对于实现抗癌药物的口服给药是至关重要的。纳米技术的出现,带动了纳米药物载体的发展,使得抗癌药物的口服给药有了很大的突破。对不同材料,主要包括合成高分子材料、天然高分子材料作为口服抗癌药物载体的特点以及体内体外的研究结果进行回顾和综述。 相似文献
11.
The aim of this study was to evaluate two in vitro models, Caco-2 monolayer and rat intestinal mucosa, regarding their linear correlation with in vivo bioavailability data of therapeutic peptide drugs after oral administration in rat and human. Furthermore the impact of molecular mass (Mm) of the according peptides on their permeability was evaluated. Transport experiments with commercially available water soluble peptide drugs were conducted using Caco-2 cell monolayer grown on transwell filter membranes and with freshly excised rat intestinal mucosa mounted in Using type chambers. Apparent permeability coefficients (P (app)) were calculated and compared with in vivo data derived from the literature. It was shown that, besides a few exceptions, the Mm of peptides linearly correlates with permeability across rat intestinal mucosa (R (2) = 0.86; y = -196.22x + 1354.24), with rat oral bioavailability (R (2) = 0.64; y = -401.90x + 1268.86) as well as with human oral bioavailability (R (2) = 0.91; y = -359.43x + 1103.83). Furthermore it was shown that P (app) values of investigated hydrophilic peptides across Caco-2 monolayer displayed lower permeability than across rat intestinal mucosa. A correlation between P (app) values across rat intestinal mucosa and in vivo oral bioavailability in human (R (2) = 0.98; y = 2.11x + 0.34) attests the rat in vitro model to be a very useful prediction model for human oral bioavailability of hydrophilic peptide drugs. Presented correlations encourage the use of the rat in vitro model for the prediction of human oral bioavailabilities of hydrophilic peptide drugs. 相似文献
12.
Carrier-mediated delivery of peptidic drugs for cancer therapy 总被引:2,自引:0,他引:2
Protein and peptide drugs are used for treatment of a variety of ailments. However, their wider use has been hindered by issues such as poor bioavailability in vivo and the cost involved in producing these drugs. This review discusses the various carrier-mediated methods used for delivery of peptide and protein drugs, with emphasis on liposomal and microspherical drug delivery systems. A brief look at the types of peptidic drugs currently in use clinically, and a brief discourse on several novel ideas for better protein delivery systems for cancer therapy is included. 相似文献
13.
Today there is considerable interest in oral peptide delivery. However, oral administration of peptides is limited by a low bioavailability and a high variability in plasma levels. A review is given of the literature describing the major barriers in peptide absorption, the basic mechanisms of intestinal peptide transport, the experimental models and the pharmaceutical approaches currently used in the investigation of peptide and protein absorption processes. 相似文献
14.
Y. Shechter M. Mironchik A. Saul E. Gershonov L. Precido-Patt K. Sasson H. Tsubery B. Mester A. Kapitkovsky S. Rubinraut Y. Vachutinski G. Fridkin M. Fridkin 《International journal of peptide research and therapeutics》2007,13(1-2):105-117
Most peptide and protein drugs are short-lived species in vivo with a circulatory half-life of several minutes. This is particularly valid for non-glycosylated proteins with a molecular
mass of less than 50 kDa. Since peptide/protein drugs are not absorbed orally, prolonged maintenance of therapeutically active
drugs in the circulatory system is of primary clinical importance. Another major obstacle of injected polypeptide drugs is
the elevated concentration of 100–1000 times above the therapeutical level that may be present in the circulatory system shortly
after administration. Such overdosing may lead to undesirable side effects such as over-stimulation or down-regulation of
receptor sites.
In this review we describe two new strategies that overcome these two problems of systemically injected peptide/protein drugs.
The first strategy includes Fmoc and FMS derivatization of peptides, proteins and low molecular-weight drugs, converting them
to inactive prodrugs that undergo reactivation with desirable pharmacokinetic patterns in body fluids. Based on this Fmoc/FMS-technology,
we have developed a second strategy, reversible pegylation. Inactive pegylated peptide/protein drugs release the native active
parental molecule at slow rates, and in homogeneous fashion under physiological conditions, thus facilitating prolonged therapeutic
effects, following a single administration. 相似文献
15.
Transdermal protein delivery by a coadministered peptide identified via phage display 总被引:7,自引:0,他引:7
Chen Y Shen Y Guo X Zhang C Yang W Ma M Liu S Zhang M Wen LP 《Nature biotechnology》2006,24(4):455-460
Efficient transdermal drug delivery of large hydrophilic drugs is challenging. Here we report that the short synthetic peptide, ACSSSPSKHCG, identified by in vivo phage display, facilitated efficient transdermal protein drug delivery through intact skin. Coadministration of the peptide and insulin to the abdominal skin of diabetic rats resulted in elevated systemic levels of insulin and suppressed serum glucose levels for at least 11 h. Significant systemic bioavailability of human growth hormone was also achieved when topically coadministered with the peptide. The transdermal-enhancing activity of the peptide was sequence specific and dose dependent, did not involve direct interaction with insulin and enabled penetration of insulin into hair follicles beyond a depth of 600 microm. Time-lapse studies suggested that the peptide creates a transient opening in the skin barrier to enable macromolecular drugs to reach systemic circulation. 相似文献
16.
Exenatide is an FDA-approved glucose-lowering peptide drug for the treatment of type 2 diabetes by subcutaneous injection. To address the issues on the inconvenience for patient use and the difficulty of oral administration of peptide drugs, chemical cross-linking of two pH-responsive biomaterials, alginate and hyaluronate, was carried out to prepare a new material for the encapsulation of exenatide as a form of microspheres. The exenatide-loaded microspheres exhibited spherical structures with excellent loading and release behaviors in the simulated gastrointestinal tract environments. After oral administration of the microspheres in db/db mice, maximum plasma concentration of exenatide appeared at 4 hours, and blood glucose was effectively reduced to a normal level within 2 hours and maintained for another 4 hours. The bioavailability of the exenatide-loaded microspheres, relative to subcutaneous injection of exenatide, reached 10.2%. Collectively, the present study demonstrated the feasibility of orally delivering exenatide with the new cross-linked biomaterial and formulation, and showed therapeutic potential for clinical applications. 相似文献
17.
O. M. Ipatova T. I. Torkhovskaya N. V. Medvedeva V. N. Prozorovsky N. D. Ivanova A. V. Shironin V. S. Baranova A. I. Archakov 《Biochemistry (Moscow) Supplemental Series B: Biomedical Chemistry》2010,4(1):82-94
Recent studies in nanotechnology resulted in the development of novel formulations with improved bioavailability. This is
especially important for oral administered drugs as the most convenient formulations for administration to patients. The review
considers processes occurring in the gastro-intestinal (GI) tract during oral administration of drugs. The increase of bioavailability
of the drug may be achieved through designing novel formulations according to the specific drug properties. These include
capsules that release pharmaceutical agents at various parts of the GI tract, floating systems that prolong the presence of
the drug in stomach, maximally dispersed forms containing surface-active soluble polymers or micelles that carry poor-soluble
drugs inside their non-polar core, agents that facilitate tight junction opening, such as caprate and chitosan, and lipid-based
formulations. The own data show the stimulating influence of phospholipid nanoparticles on peroral absorption of the drug,
indomethacin, in rats and on passage of transport marker and drugs through Caco-2 cell monolayer in vitro. The review summarizes
current understanding of factors that influence the bioavailability of the oral drug formulations, currently used models for
pharmacokinetic studies, and various approaches to developing novel pharmaceutical formulations that increase the bioavailability
of the drugs. 相似文献